vs

Side-by-side financial comparison of COMPUGEN LTD (CGEN) and KOSS CORP (KOSS). Click either name above to swap in a different company.

COMPUGEN LTD is the larger business by last-quarter revenue ($3.5M vs $2.9M, roughly 1.2× KOSS CORP). KOSS CORP runs the higher net margin — -19.8% vs -410.1%, a 390.4% gap on every dollar of revenue. On growth, KOSS CORP posted the faster year-over-year revenue change (-19.6% vs -61.8%). KOSS CORP produced more free cash flow last quarter ($-1.1M vs $-18.8M).

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big compan...

Koss Corporation is a company in Milwaukee, Wisconsin, US that manufactures headphones. The company created the first high-fidelity stereo headphones in 1958.

CGEN vs KOSS — Head-to-Head

Bigger by revenue
CGEN
CGEN
1.2× larger
CGEN
$3.5M
$2.9M
KOSS
Growing faster (revenue YoY)
KOSS
KOSS
+42.2% gap
KOSS
-19.6%
-61.8%
CGEN
Higher net margin
KOSS
KOSS
390.4% more per $
KOSS
-19.8%
-410.1%
CGEN
More free cash flow
KOSS
KOSS
$17.7M more FCF
KOSS
$-1.1M
$-18.8M
CGEN

Income Statement — Q2 FY2025 vs Q2 FY2026

Metric
CGEN
CGEN
KOSS
KOSS
Revenue
$3.5M
$2.9M
Net Profit
$-14.5M
$-565.4K
Gross Margin
29.0%
Operating Margin
-475.1%
-35.5%
Net Margin
-410.1%
-19.8%
Revenue YoY
-61.8%
-19.6%
Net Profit YoY
-54.7%
-700.6%
EPS (diluted)
$-0.16
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CGEN
CGEN
KOSS
KOSS
Q4 25
$2.9M
Q3 25
$4.1M
Q2 25
$3.5M
$3.1M
Q1 25
$2.8M
Q4 24
$3.6M
Q3 24
$3.2M
Q2 24
$9.3M
$2.9M
Q1 24
$2.6M
$2.6M
Net Profit
CGEN
CGEN
KOSS
KOSS
Q4 25
$-565.4K
Q3 25
$243.7K
Q2 25
$-14.5M
$-232.7K
Q1 25
$-316.7K
Q4 24
$94.1K
Q3 24
$-419.5K
Q2 24
$-9.4M
$-110.4K
Q1 24
$7.3M
$-313.8K
Gross Margin
CGEN
CGEN
KOSS
KOSS
Q4 25
29.0%
Q3 25
40.0%
Q2 25
36.0%
Q1 25
39.0%
Q4 24
39.5%
Q3 24
36.6%
Q2 24
60.5%
40.4%
Q1 24
17.9%
31.9%
Operating Margin
CGEN
CGEN
KOSS
KOSS
Q4 25
-35.5%
Q3 25
-1.1%
Q2 25
-475.1%
-14.2%
Q1 25
-18.7%
Q4 24
-4.0%
Q3 24
-19.9%
Q2 24
-128.5%
-11.0%
Q1 24
-23.1%
Net Margin
CGEN
CGEN
KOSS
KOSS
Q4 25
-19.8%
Q3 25
6.0%
Q2 25
-410.1%
-7.5%
Q1 25
-11.4%
Q4 24
2.6%
Q3 24
-13.1%
Q2 24
-101.4%
-3.8%
Q1 24
284.0%
-11.9%
EPS (diluted)
CGEN
CGEN
KOSS
KOSS
Q4 25
$-0.06
Q3 25
$0.03
Q2 25
$-0.16
$-0.02
Q1 25
$-0.03
Q4 24
$0.01
Q3 24
$-0.05
Q2 24
$-0.10
$-0.01
Q1 24
$89505618.00
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CGEN
CGEN
KOSS
KOSS
Cash + ST InvestmentsLiquidity on hand
$35.3M
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$50.3M
$30.3M
Total Assets
$106.5M
$36.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CGEN
CGEN
KOSS
KOSS
Q4 25
$15.5M
Q3 25
$16.5M
Q2 25
$35.3M
$15.7M
Q1 25
$13.0M
Q4 24
$9.7M
Q3 24
$11.9M
Q2 24
$44.6M
$14.9M
Q1 24
$39.3M
$9.9M
Stockholders' Equity
CGEN
CGEN
KOSS
KOSS
Q4 25
$30.3M
Q3 25
$30.9M
Q2 25
$50.3M
$30.6M
Q1 25
$30.7M
Q4 24
$31.0M
Q3 24
$30.8M
Q2 24
$58.3M
$31.1M
Q1 24
$65.6M
$31.1M
Total Assets
CGEN
CGEN
KOSS
KOSS
Q4 25
$36.8M
Q3 25
$37.7M
Q2 25
$106.5M
$37.2M
Q1 25
$37.3M
Q4 24
$37.4M
Q3 24
$38.1M
Q2 24
$110.2M
$37.2M
Q1 24
$121.3M
$37.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CGEN
CGEN
KOSS
KOSS
Operating Cash FlowLast quarter
$-18.6M
$-760.8K
Free Cash FlowOCF − Capex
$-18.8M
$-1.1M
FCF MarginFCF / Revenue
-530.8%
-37.5%
Capex IntensityCapex / Revenue
6.5%
10.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-546.7K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CGEN
CGEN
KOSS
KOSS
Q4 25
$-760.8K
Q3 25
$762.6K
Q2 25
$-18.6M
$-534.9K
Q1 25
$370.4K
Q4 24
$-252.0K
Q3 24
$201.6K
Q2 24
$39.7M
$-174.0K
Q1 24
$328.6K
Free Cash Flow
CGEN
CGEN
KOSS
KOSS
Q4 25
$-1.1M
Q3 25
$761.5K
Q2 25
$-18.8M
$-541.8K
Q1 25
$306.2K
Q4 24
$-314.3K
Q3 24
$-155.6K
Q2 24
$39.7M
$-174.8K
Q1 24
$269.3K
FCF Margin
CGEN
CGEN
KOSS
KOSS
Q4 25
-37.5%
Q3 25
18.7%
Q2 25
-530.8%
-17.6%
Q1 25
11.0%
Q4 24
-8.8%
Q3 24
-4.9%
Q2 24
428.3%
-6.0%
Q1 24
10.2%
Capex Intensity
CGEN
CGEN
KOSS
KOSS
Q4 25
10.9%
Q3 25
0.0%
Q2 25
6.5%
0.2%
Q1 25
2.3%
Q4 24
1.8%
Q3 24
11.2%
Q2 24
0.4%
0.0%
Q1 24
2.3%
Cash Conversion
CGEN
CGEN
KOSS
KOSS
Q4 25
Q3 25
3.13×
Q2 25
Q1 25
Q4 24
-2.68×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons